FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roger Cohen

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Devices

Drug Delivery Systems

Physiology

Co-author Network

Publications

TOP 3
Aruna Turaka; Tianyu Li; Navesh Sharma; Linna Li; Nicos Nicolaou; Ranee Mehra; Barbara Burtness; Roger B Cohen; Miriam N Lango; Eric M Horwitz; John A Ridge; Steven Feigenberg
Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.
Miriam N Lango; Brian Egleston; Kevin Ende; Steven Feigenberg; David J D'Ambrosio; Roger B Cohen; Sidrah Ahmad; Nicos Nicolaou; John A Ridge
Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation.
Mohamedtaki A Tejani; Roger B Cohen; Ranee Mehra
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roger Cohen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Aruna Turaka; Tianyu Li; Navesh Sharma; Linna Li; Nicos Nicolaou; Ranee Mehra; Barbara Burtness; Roger B Cohen; Miriam N Lango; Eric M Horwitz; John A Ridge; Steven Feigenberg
Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.
American journal of clinical oncology 2010;33(6):599-603.
2010: Miriam N Lango; Brian Egleston; Kevin Ende; Steven Feigenberg; David J D'Ambrosio; Roger B Cohen; Sidrah Ahmad; Nicos Nicolaou; John A Ridge
Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation.
Head & neck 2010;32(3):341-7.
2010: Mohamedtaki A Tejani; Roger B Cohen; Ranee Mehra
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.
Biologics : targets & therapy 2010;4():173-85.
2009: Roger B Cohen; Suzanne F Jones; Charu Aggarwal; Margaret von Mehren; Jonathan Cheng; David R Spigel; F Anthony Greco; Mariangela Mariani; Maurizio Rocchetti; Roberta Ceruti; Silvia Comis; Bernard Laffranchi; Jurgen Moll; Howard A Burris
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(21):6694-701.
2009: Nancy L Lewis; Lionel D Lewis; Joseph P Eder; Nandi J Reddy; Feng Guo; Kristen J Pierce; Anthony J Olszanski; Roger B Cohen
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5262-9.
2009: Hossein Borghaei; Katherine Alpaugh; Gunnar Hedlund; Göran Forsberg; Corey Langer; André Rogatko; Robert Hawkins; Svein Dueland; Ulrik Lassen; Roger B Cohen
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(25):4116-23.
2008: Ranee Mehra; Roger B Cohen
New agents in the treatment for malignancies of the salivary and thyroid glands.
Hematology/oncology clinics of North America 2008;22(6):1279-95, xi.
2008: Ranee Mehra; Roger B Cohen; Barbara Burtness
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Clinical advances in hematology & oncology : H&O 2008;6(10):742-50.
2008: Margaret von Mehren; Russell J Schilder; Jonathan D Cheng; E Temmer; T M Cardoso; F G Renshaw; E Bayever; Peter Zannikos; Z Yuan; Roger B Cohen
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1802-9.
2008: Ranee Mehra; Roger B Cohen; Paul M Harari
EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Current oncology reports 2008;10(2):176-84.
2008: Igor Astsaturov; Roger B Cohen; Paul M Harari
Clinical application of EGFR inhibitors in head and neck squamous cell cancer.
Cancer treatment and research 2008;139():135-52.
2007: Igor Astsaturov; Roger B Cohen; Paul M Harari
EGFR-targeting monoclonal antibodies in head and neck cancer.
Current cancer drug targets 2007;7(7):650-65.
2007: David J D'Ambrosio; Roger B Cohen; Jon Glass; Andre Konski; Mark K. Buyyounouski; Steven Feigenberg
Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report.
Journal of neuro-oncology 2007;85(1):77-9.
2007: Desmond Curran; Jordi Giralt; Paul M Harari; K. Kian Ang; Roger B Cohen; Merrill S Kies; Jacek Jassem; José Baselga; Eric K Rowinsky; Nadia Amellal; Sylvie Comte; James A. Bonner
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2191-7.
2007: Roger B Cohen; Corey J Langer; George Rajan Simon; Peter David Eisenberg; John Daniel Hainsworth; Stefan Madajewicz; Thomas Michael Cosgriff; Kristen Pierce; Huiping Xu; Katherine Liau; Diane Healey
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cancer chemotherapy and pharmacology 2007;60(1):81-9.
2007: Paul M Harari; Roger B Cohen; David Raben; Jeffrey N Myers; Everett E Vokes; Randal S Weber; K. Kian Ang
The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium.
International journal of radiation oncology, biology, physics 2007;69(2 Suppl):S1-3.
2006: Igor Astsaturov; Roger B Cohen; Paul M Harari
EGFR-targeting monoclonal antibodies in head and neck cancer.
Current cancer drug targets 2006;6(8):691-710.
2006: Igor Astsaturov; Roger B Cohen; Paul M Harari
Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
Expert review of anticancer therapy 2006;6(9):1179-93.
2006: Mary Cianfrocca; K A Kimmel; James Gallo; T Cardoso; M M Brown; Gary R Hudes; Nancy Lewis; L Weiner; G N Lam; S C Brown; David E Shaw; Andrew P Mazar; Roger B Cohen
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
British journal of cancer 2006;94(11):1621-6.
2006: James A. Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K. Kian Ang
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
The New England journal of medicine 2006;354(6):567-78.
2005: Steven J Cohen; Roger B Cohen; Neal J Meropol
Targeting signal transduction pathways in colorectal cancer--more than skin deep.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5374-85.
2005: Noel M Kramer; Eric M Horwitz; Jonathan Cheng; John A Ridge; Steven Feigenberg; Roger B Cohen; Nicos Nicolaou; Eric Sherman; James S Babb; Jason A Damsker; Corey J Langer
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Head & neck 2005;27(5):406-14.
2004: Corey J Langer; Yi Li; Timothy Jennings; Ronald C DeConti; Suresh Nair; Roger B Cohen; Arlene A Forastiere
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
Cancer investigation 2004;22(6):823-31.
2003: Roger B Cohen
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Clinical colorectal cancer 2003;2(4):246-51.
2001: Roger B Cohen; K A Dittrich
Anti-TNF therapy and malignancy - a critical review.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2001;15(6):376-84.